date,ticker,pct_change_prev_close,day_percent_change,max_day_percent_change,source,title,description,url,same_or_prev,date_time_story,nltk_pos_minus_neg_title,nltk_pos_minus_neg_description,nltk_pos_minus_neg_article,nltk_compound_title,nltk_compound_description,nltk_compound_article,tb_polarity_title,tb_polarity_description,tb_polarity_article,stanza_sentiment_article,open_price,close_price,percent_change,max_percent_change,volume,average_volume
9/28/15,HRTX,-23.5,-24.18831169,0.032467532,bw,Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL¬Æ at the ASCO Breast Cancer Symposium,"Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced...",http://www.businesswire.com/news/home/20150928005483/en/Heron-Therapeutics-Announces-Oral-Presentation-of-Data-from-Completed-Phase-3-MAGIC-Study-for-SUSTOL%C2%AE-at-the-ASCO-Breast-Cancer-Symposium,same,09/28/2015 08:00,-0.14,0.228,-0.017,-0.6486,0.6705,-0.8533,0.5,0.03125,0.13474517906336086,-0.16666666666666666,30.8,23.35,-0.24188311688311687,0.00032467532467526006,7301020,1022729
10/27/15,AGIO,24.8,26.46875,27.328125,gnw,Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC,"CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...",https://www.globenewswire.com/news-release/2015/10/26/780126/31990/en/Agios-to-Present-Clinical-Data-from-Ongoing-AG-120-Phase-1-Trial-in-Advanced-Solid-Tumors-at-AACR-NCI-EORTC.html,prev,10/26/2015 16:35,0.205,-0.145,0.017999999999999995,0.3818,-0.6597,-0.128,0.13333333333333333,0.3,0.129397233201581,0.6666666666666666,64,80.94,0.26468749999999996,0.2732812499999999,2193228,764887
11/5/15,EYEG,58.1,56.27376426,90.11406844,gnw,EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients,"WALTHAM, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (""EyeGate"" or the ""Company""), a specialty pharmaceutical company that focuses on developing and...",https://www.globenewswire.com/news-release/2015/11/05/784089/33326/en/EyeGate-Announces-Interim-Data-From-Phase-1b-2a-Clinical-Trial-of-Iontophoretic-EGP-437-Ophthalmic-Solution-in-Macular-Edema-Patients.html,same,11/05/2015 08:45,0.113,0.0,0.059000000000000004,0.3182,0.0,0.9843,0.0,0.0,0.17642906336088152,-0.15,39.45,61.65,0.5627376425855511,0.9011406844106462,186332.73333333334,18072
3/1/16,PTCT,-30.5,-26.58730159,1.71957672,bw,"Robbins Arroyo LLP Is Investigating the Officers and Directors of PTC Therapeutics, Inc. (PTCT) on Behalf of Shareholders","Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQGS: PTCT) violated federal securities laws by issuing materially...",http://www.businesswire.com/news/home/20160229007033/en/Robbins-Arroyo-LLP-Is-Investigating-the-Officers-and-Directors-of-PTC-Therapeutics-Inc.-PTCT-on-Behalf-of-Shareholders,prev,02/29/2016 20:41,0.0,0.029000000000000012,0.019000000000000003,0.0,-0.0258,0.4986,0.0,0.007142857142857131,0.020810142238713664,-0.3125,7.56,5.55,-0.26587301587301587,0.0171957671957673,13132811,516483
3/2/16,ADXS,26.6,20.09646302,20.41800643,gnw,Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting,"PRINCETON, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a Phase 2...",https://www.globenewswire.com/news-release/2016/03/02/816132/29755/en/Advaxis-Study-in-Head-and-Neck-Cancer-Selected-for-Late-Breaking-Poster-at-the-American-Association-for-Cancer-Research-Annual-Meeting.html,same,03/02/2016 07:05,-0.328,-0.155,-0.048999999999999995,-0.8689,-0.6597,-0.9893,0.0,0.0,0.14980938416422282,-0.2222222222222222,93.3,112.05,0.2009646302250804,0.20418006430868166,178489.8,4514554
5/11/16,CCXI,53.8,52.3178808,60.77152318,gnw,"ChemoCentryx to Host R&D Day on May 18, 2016","MOUNTAIN VIEW, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat...",https://www.globenewswire.com/news-release/2016/05/11/838884/19219/en/ChemoCentryx-to-Host-R-D-Day-on-May-18-2016.html,same,05/11/2016 08:30,0.0,0.0,-0.016999999999999998,0.0,0.0,-0.4019,0.0,0.0,0.13484848484848486,0.0,3.02,4.6,0.5231788079470198,0.6077152317880794,20721622,467439
8/1/16,APVO,-22.1,-32.63403263,0.932400932,bw,Aptevo Therapeutics Secures $35 Million Term Loan Agreement,"Aptevo Therapeutics Inc. (‚ÄúAptevo‚Äù; ‚Äúthe Company‚Äù) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has reached agreemen...",http://www.businesswire.com/news/home/20160801005439/en/Aptevo-Therapeutics-Secures-35-Million-Term-Loan-Agreement,same,08/01/2016 07:30,0.478,0.231,0.13699999999999998,0.6705,0.6486,0.9862,0.0,0.0,0.14151785714285714,0.0,60.06,40.46,-0.32634032634032634,0.009324009324009242,207108.78571428577,33627
8/1/16,APVO,-22.1,-32.63403263,0.932400932,bw,Aptevo Therapeutics Completes Separation from Emergent BioSolutions,"Aptevo Therapeutics Inc. (‚ÄúAptevo‚Äù) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emerg...",http://www.businesswire.com/news/home/20160801005403/en/Aptevo-Therapeutics-Completes-Separation-from-Emergent-BioSolutions,same,08/01/2016 07:00,0.0,0.182,0.151,0.0,0.5994,0.9903,0.0,0.0,0.011544795783926221,0.2222222222222222,60.06,40.46,-0.32634032634032634,0.009324009324009242,207108.78571428577,33627
8/8/16,FATE,22.7,21.59624413,23.94366197,gnw,Fate Therapeutics Announces $10.3 Million Common Stock Private Placement,"SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...",https://www.globenewswire.com/news-release/2016/08/08/862343/24675/en/Fate-Therapeutics-Announces-10-3-Million-Common-Stock-Private-Placement.html,same,08/08/2016 08:00,0.0,0.115,0.129,0.0,0.4588,0.9884,-0.15,0.0,-0.012745098039215683,-0.3333333333333333,2.13,2.59,0.21596244131455397,0.23943661971830998,1859315,1054226
8/23/16,CLVS,27.2,25.84699454,36.44535519,bw,FDA Accepts Clovis Oncology‚Äôs New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis‚Äô New Drug Application (NDA) for accelerated approval of rucaparib and granted...",http://www.businesswire.com/news/home/20160823006191/en/FDA-Accepts-Clovis-Oncology%E2%80%99s-New-Drug-Application-for-Rucaparib-for-Priority-Review-for-the-Treatment-of-Advanced-Mutant-BRCA-Ovarian-Cancer,same,08/23/2016 14:30,-0.0040000000000000036,0.161,0.044,-0.2732,0.6369,0.866,0.2681818181818182,0.13636363636363635,0.14498106060606059,0.0,18.3,23.03,0.25846994535519124,0.36445355191256823,17497413,4622851
9/19/16,SRPT,73.9,69.87157237,95.00173551,bw,"Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51‚Ñ¢ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51","Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXO...",http://www.businesswire.com/news/home/20160919006292/en/Sarepta-Therapeutics-Announces-FDA-Accelerated-Approval-of-EXONDYS-51%E2%84%A2-eteplirsen-injection-an-Exon-Skipping-Therapy-to-Treat-Duchenne-Muscular-Dystrophy-DMD-Patients-Amenable-to-Skipping-Exon-51,same,09/19/2016 13:39,0.188,0.267,0.03200000000000001,0.7003,0.7906,0.928,0.2,0.5,0.11160140364685821,-0.14285714285714285,28.81,48.94,0.6987157237070462,0.95001735508504,51288875,926992
1/10/17,SRPT,21.2,20.51526718,25.1908397,bw,Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children‚Äôs Hospital for Microdystrophin Gene Therapy Program,"Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children‚Äô...",http://www.businesswire.com/news/home/20170110005558/en/Sarepta-Therapeutics-Enters-into-Research-Agreement-and-Option-Agreement-with-Nationwide-Children%E2%80%99s-Hospital-for-Microdystrophin-Gene-Therapy-Program,same,01/10/2017 08:30,0.286,0.225,0.19,0.7506,0.7269,0.9914,0.0,0.25,0.175,0.2,31.44,37.89,0.20515267175572516,0.2519083969465648,14830412,926992
1/10/17,SRPT,21.2,20.51526718,25.1908397,bw,Sarepta Therapeutics Enters into License Agreement with Nationwide Children‚Äôs Hospital for Galgt2 Gene Therapy Program,"Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children‚Äôs...",http://www.businesswire.com/news/home/20170110005563/en/Sarepta-Therapeutics-Enters-into-License-Agreement-with-Nationwide-Children%E2%80%99s-Hospital-for-Galgt2-Gene-Therapy-Program,same,01/10/2017 08:30,0.186,0.275,0.086,0.4939,0.765,0.9528,0.0,0.25,0.11666666666666667,-0.125,31.44,37.89,0.20515267175572516,0.2519083969465648,14830412,926992
3/16/17,MCRB,37.1,27.1,33.15,bw,Seres Therapeutics to Initiate New SER-109 Clinical Study,"Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical study (ECOSPOR III) in patients with multip...",http://www.businesswire.com/news/home/20170316005279/en/Seres-Therapeutics-to-Initiate-New-SER-109-Clinical-Study,same,03/16/2017 07:00,0.0,0.0,0.101,0.0,0.0,0.9901,0.13636363636363635,0.13636363636363635,0.15103782182729555,0.058823529411764705,10,12.71,0.2710000000000001,0.33149999999999996,4364616,872566
3/31/17,ACOR,-21.5,-21.34831461,2.247191011,bw,U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling,"Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the United States District Court for the District of Delaware upheld U.S. Patent No. 5,540,938 (the ‚Äò938 patent), which pertains to the f...",http://www.businesswire.com/news/home/20170331005631/en/U.S.-District-Court-Issues-Decision-to-Invalidate-Four-AMPYRA-Patents-Company-Will-Appeal-Ruling,same,03/31/2017 12:31,0.0,0.017,0.018999999999999996,0.0,0.1531,0.5267,0.0,0.0,-0.049999999999999996,-0.16666666666666666,160.2,126,-0.21348314606741567,0.022471910112359696,1607908.8333333333,175238
5/17/17,SNDX,44.6,25.74074074,41.99074074,gnw,Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies,"WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (""Syndax,"" the ""Company"" or ""we"") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...",https://www.globenewswire.com/news-release/2017/05/16/986671/0/en/Syndax-Pharmaceuticals-Announces-Advancement-of-ENCORE-601-in-Non-Small-Cell-Lung-Cancer-Patients-with-Disease-Progression-on-or-After-PD-1-Therapies.html,prev,05/16/2017 17:26,-0.18,0.102,0.013000000000000005,-0.6597,0.3818,0.5859,0.0,0.0,0.06234402852049912,0.0,10.8,13.58,0.2574074074074073,0.4199074074074074,4281688,1253209
5/18/17,GLYC,98.7,36.27075351,47.89272031,bw,"GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML","GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in...",http://www.businesswire.com/news/home/20170518005294/en/GlycoMimetics-Announces-High-Overall-Response-Rates-Low-Induction-Mortality%C2%A0Promising-Initial-Survival-Outcomes-and-Supportive-Biomarker-Data-from-Phase-12-Trial-of-GMI-1271-in-AML,same,05/18/2017 06:30,0.24,-0.097,0.076,0.8374,-0.4404,0.9948,0.14333333333333334,0.13636363636363635,0.14104448742746617,-0.09375,7.83,10.67,0.3627075351213282,0.4789272030651341,36833606,780094
7/19/17,AEZS,129.4,50.96774194,80.64516129,bw,"NDA for Macrilen‚Ñ¢ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date","Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the ‚ÄúCompany‚Äù) today announced that it has been notified by the U.S. Food and Drug Administration (‚ÄúFDA‚Äù), that the Company‚Äôs New Drug Application (‚ÄúND...",http://www.businesswire.com/news/home/20170718006321/en/NDA-for-Macrilen%E2%84%A2-for-the-Evaluation-of-Growth-Hormone-Deficiency-in-Adults-Granted-December-30-2017-PDUFA-Date,prev,07/18/2017 17:00,0.223,0.0,0.12400000000000001,0.5574,0.0,0.9618,0.0,0.13636363636363635,0.2566287878787879,0.25,1.55,2.34,0.5096774193548386,0.8064516129032256,61447485,5129198
7/26/17,EGRX,-23.8,-24.02846975,2.320284698,bw,Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application,"Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (‚ÄúEagle‚Äù or ‚Äúthe Company‚Äù) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its 505(...",http://www.businesswire.com/news/home/20170726005970/en/Eagle-Pharmaceuticals-Receives-Complete-Response-Letter-from-FDA-on-RYANODEX-for-Exertional-Heat-Stroke-Application,same,07/26/2017 12:30,0.0,0.0,0.035,0.0,0.0,0.5994,0.1,0.1,0.2566233766233766,-0.25,70.25,53.37,-0.24028469750889683,0.023202846975088905,1862111,123573
8/15/17,TNDM,37.3,37.27272727,42.72727273,bw,Tandem Diabetes Care Begins Enrollment in Pivotal Trial for First Touchscreen Insulin Pump with Predictive Low Glucose Suspend (PLGS),"Tandem Diabetes Care¬Æ, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced enrollment of the first pati...",http://www.businesswire.com/news/home/20170815005421/en/Tandem-Diabetes-Care-Begins-Enrollment-in-Pivotal-Trial-for-First-Touchscreen-Insulin-Pump-with-Predictive-Low-Glucose-Suspend-PLGS,same,08/15/2017 08:30,-0.04999999999999999,0.091,-0.006999999999999999,-0.0516,0.4215,-0.4221,0.25,0.1625,0.12013314967860425,-0.38461538461538464,0.55,0.755,0.37272727272727263,0.4272727272727272,2328943,751683
11/2/17,DRNA,28.2,20.5,31.49833333,bw,Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH),"Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreem...",http://www.businesswire.com/news/home/20171102005456/en/Boehringer-Ingelheim-and-Dicerna-Announce-Collaboration-to-Develop-Novel-Treatments-for-Chronic-Liver-Diseases-including-Nonalcoholic-Steatohepatitis-NASH,same,11/02/2017 06:30,0.119,0.0,0.088,0.3182,0.0,0.9935,0.0,0.0,0.12175252525252525,0.0,6,7.23,0.20500000000000007,0.31498333333333334,2255098,720243
12/19/17,TYME,20.6,21.42857143,38.33333333,gnw,Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium,"NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its...",https://www.globenewswire.com/news-release/2017/12/19/1266109/0/en/Tyme-to-Present-Efficacy-Data-on-SM-88-in-Pancreatic-Cancer-at-2018-ASCO-Gastrointestinal-Cancers-Symposium.html,same,12/19/2017 08:00,-0.227,-0.155,-0.04,-0.6597,-0.6597,-0.891,0.0,0.13636363636363635,0.1143939393939394,0.0,4.2,5.1,0.21428571428571416,0.3833333333333332,474390,2012974
12/28/17,EARS,33.1,23.8,32,gnw,"Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018","Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...",https://www.globenewswire.com/news-release/2017/12/28/1275751/0/en/Auris-Medical-News-Release-Auris-Medical-to-Provide-Update-on-Its-AM-111-Hearing-Loss-Program-on-Thursday-January-4-2018.html,same,12/28/2017 08:30,-0.108,0.179,0.016,-0.3182,0.5859,0.4939,0.0,0.13333333333333333,0.08526170798898071,0.0,100,123.8,0.23799999999999996,0.32,55549.46499999997,7357741
1/5/18,KALA,-29.3,-23.40625,0,bw,Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced topline results from its two Phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and...",http://www.businesswire.com/news/home/20180105005184/en/Kala-Pharmaceuticals-Announces-Topline-Results-for-Two-Phase-3-Trials-STRIDE-1-and-STRIDE-2-of-KPI-121-0.25-in-Dry-Eye-Disease,same,01/05/2018 07:00,0.0,0.185,0.033999999999999996,0.0,0.7096,0.9779,-0.06666666666666665,-0.033333333333333326,0.17209388971684056,-0.375,16,12.255,-0.23406249999999995,0.0,2970898,2105682
1/5/18,KALA,-29.3,-23.40625,0,bw,Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) tech...",http://www.businesswire.com/news/home/20180105005187/en/Kala-Pharmaceuticals-Announces-New-Drug-Application-for-INVELTYSTM-KPI-121-1-Has-Been-Accepted-for-Review-by-the-U.S.-Food-and-Drug-Administration,same,01/05/2018 06:50,0.091,0.11,0.057,0.2732,0.3818,0.9702,0.13636363636363635,0.0,0.16319444444444442,-0.07692307692307693,16,12.255,-0.23406249999999995,0.0,2970898,2105682
4/10/18,VTVT,-78.1,-29.26732673,0,bw,vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer‚Äôs Disease,"vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company‚Äôs Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer‚Äô...",http://www.businesswire.com/news/home/20180409006413/en/vTv-Therapeutics-Announces-Topline-Results-from-the-First-STEADFAST-Phase-3-Study-Evaluating-Azeliragon-in-People-with-Mild-Alzheimer%E2%80%99s-Disease,prev,04/09/2018 16:46,0.132,0.095,0.12200000000000001,0.4084,0.4084,0.9873,0.3277777777777778,0.3666666666666667,0.22728070175438597,-0.3333333333333333,1.01,0.7144,-0.29267326732673266,0.0,8110712,14212883
6/4/18,DCPH,47.9,42.15213358,42.5974026,bw,Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has commenced a propose...",http://www.businesswire.com/news/home/20180604006385/en/Deciphera-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock,same,06/04/2018 16:12,0.0,0.0,0.069,0.0,0.0,0.9272,-0.15,0.0,0.065625,-0.375,26.95,38.31,0.4215213358070502,0.425974025974026,1869524,354213
8/23/18,OBLN,52,33,43,gnw,Obalon Therapeutics to Raise $10 Million in Private Placement,"SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...",https://www.globenewswire.com/news-release/2018/08/23/1555881/0/en/Obalon-Therapeutics-to-Raise-10-Million-in-Private-Placement.html,same,08/23/2018 09:02,0.0,0.0,0.12200000000000001,0.0,0.0,0.9849,0.0,0.08333333333333333,-0.03643892339544513,-0.3333333333333333,20,26.6,0.33000000000000007,0.43000000000000005,273664.19999999995,1818630
9/10/18,ACOR,-24.5,-25.17985612,0.179856115,bw,U.S. Court of Appeals for the Federal Circuit Upholds District Court‚Äôs Decision to Invalidate AMPYRA¬Æ (dalfampridine) Patents,"Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of...",http://www.businesswire.com/news/home/20180910005687/en/U.S.-Court-of-Appeals-for-the-Federal-Circuit-Upholds-District-Court%E2%80%99s-Decision-to-Invalidate-AMPYRA%C2%AE-dalfampridine-Patents,same,09/10/2018 11:47,0.0,0.162,0.06,0.0,0.6808,0.8805,0.0,0.0,-0.019166666666666665,-0.14285714285714285,166.8,124.8,-0.2517985611510792,0.0017985611510790344,610738.6666666666,175238
9/24/18,SPPI,-22.7,-22.44131455,0.610328638,bw,Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients,"Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announc...",http://www.businesswire.com/news/home/20180924005695/en/Spectrum-Pharmaceuticals-Announces-Release-of-Updated-Poziotinib-Data-From-MD-Anderson-Phase-2-Study-in-Non-Small-Cell-Lung-Cancer-Patients,same,09/24/2018 11:40,-0.196,0.0,0.0020000000000000018,-0.6597,0.0,-0.6509,0.0,0.2,-0.055750962000961996,0.05263157894736842,21.3,16.52,-0.22441314553990616,0.006103286384976479,7629095,2299121
9/25/18,TGTX,-44.3,-21.96969697,1.515151515,gnw,TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial,"NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX) today announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review...",https://www.globenewswire.com/news-release/2018/09/25/1575546/8790/en/TG-Therapeutics-Announces-Update-Regarding-UNITY-CLL-Phase-3-Trial.html,same,09/25/2018 07:00,0.0,0.088,0.142,0.0,0.4215,0.9975,0.0,0.06818181818181818,0.1384063852813853,-0.35294117647058826,6.6,5.15,-0.2196969696969696,0.015151515151515233,13069959,1531647
10/1/18,OMER,-42.8,-43.11328443,1.329665852,bw,Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy,Omeros Corporation (NASDAQ: OMER) today announced positive data from the company‚Äôs ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with i...,http://www.businesswire.com/news/home/20181001005895/en/Omeros-Corporation-Announces-Additional-Positive-Data-for-OMS721-in-IgA-Nephropathy,same,10/01/2018 14:15,0.265,0.107,0.03899999999999999,0.5574,0.5574,0.9928,0.22727272727272727,0.22727272727272727,0.07253335042150831,-0.6153846153846154,24.54,13.96,-0.43113284433577825,0.013296658516707409,4441596,536218
10/12/18,EARS,44.1,26.04501608,28.61736334,gnw,"Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018","Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...",https://www.globenewswire.com/news-release/2018/10/12/1620480/0/en/Auris-Medical-to-provide-update-on-intranasal-betahistine-program-on-Wednesday-October-17-2018.html,same,10/12/2018 07:30,0.0,0.173,0.075,0.0,0.5859,0.8481,0.0,0.13333333333333333,0.084688995215311,0.0,15.55,19.6,0.2604501607717042,0.2861736334405144,1772801.6000000003,7357741
11/12/18,CNCE,-21.6,-23.18486882,0,bw,Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with...",http://www.businesswire.com/news/home/20181112005162/en/Concert-Pharmaceuticals-Reports-Positive-CTP-543-Results-from-Interim-Analysis-of-Phase-2a-Trial-in-Patients-with-Alopecia-Areata,same,11/12/2018 07:00,0.175,0.0,0.0049999999999999975,0.5574,0.0,0.3597,0.22727272727272727,0.25,0.08135416666666667,-0.45454545454545453,16.39,12.59,-0.2318486882245272,0.0,447541,420523
11/26/18,TYME,30.2,27.27272727,36.36363636,gnw,"Tyme Technologies, Inc. to Present at the Piper Jaffray Healthcare Conference on November 28th","NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...",https://www.globenewswire.com/news-release/2018/11/26/1656913/0/en/Tyme-Technologies-Inc-to-Present-at-the-Piper-Jaffray-Healthcare-Conference-on-November-28th.html,same,11/26/2018 16:01,0.0,-0.233,-0.053,0.0,-0.7906,-0.7906,0.0,0.06818181818181818,0.10255681818181818,0.0,2.2,2.8,0.27272727272727254,0.36363636363636354,1863440,2012974
11/26/18,TYME,30.2,27.27272727,36.36363636,gnw,Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium,"NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...",https://www.globenewswire.com/news-release/2018/11/26/1656548/0/en/Tyme-Announces-the-Presentation-of-Clinical-Abstracts-at-the-2019-Gastrointestinal-Cancers-Symposium.html,same,11/26/2018 08:00,0.0,-0.155,-0.081,0.0,-0.6597,-0.8689,0.0,0.13636363636363635,0.022727272727272724,0.0,2.2,2.8,0.27272727272727254,0.36363636363636354,1863440,2012974
12/7/18,DMAC,-47,-22.5,6.25,gnw,DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING,"MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (‚ÄúDiaMedica‚Äù) (NASDAQ:DMAC) (TSX‚ÄëV:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...",https://www.globenewswire.com/news-release/2018/12/07/1663697/0/en/DIAMEDICA-ANNOUNCES-PRICING-OF-INITIAL-PUBLIC-OFFERING-AND-NASDAQ-LISTING.html,same,12/07/2018 07:00,0.0,0.0,0.098,0.0,0.0,0.9738,0.0,0.0,-0.009027777777777773,-0.1,4,3.1,-0.22499999999999998,0.0625,1123987,91389
12/27/18,BTAI,80.9,32.12121212,50.60606061,gnw,BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation,"NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (‚ÄúBTI‚Äù or ‚ÄúCompany‚Äù) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its...",https://www.globenewswire.com/news-release/2018/12/27/1678491/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL501-for-Acute-Treatment-of-Agitation.html,same,12/27/2018 08:00,-0.133,0.065,0.062000000000000006,-0.25,0.25,0.9709,0.4,0.16818181818181818,0.1100259236887144,0.14285714285714285,3.3,4.36,0.3212121212121214,0.5060606060606061,2717547,506671
1/31/19,AVEO,-60.5,-34.63551402,2.803738318,bw,AVEO Oncology Announces NDA Timing Update,AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA¬Æ)...,http://www.businesswire.com/news/home/20190131005509/en/AVEO-Oncology-Announces-NDA-Timing-Update,same,01/31/2019 09:00,0.0,0.068,0.05,0.0,0.2732,0.9536,0.0,0.13636363636363635,0.06514901764901765,-0.23076923076923078,10.7,6.994,-0.3463551401869159,0.028037383177570162,2954108.6999999993,1400188
3/8/19,ALT,-36.6,-20.66115703,3.305785124,gnw,Altimmune Announces $14 million Registered Direct Offering,"GAITHERSBURG, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two...",https://www.globenewswire.com/news-release/2019/03/08/1750641/0/en/Altimmune-Announces-14-million-Registered-Direct-Offering.html,same,03/08/2019 09:29,0.0,0.118,0.047,0.0,0.4939,0.967,0.1,0.0,-0.04356060606060606,-0.06666666666666667,3.63,2.88,-0.2066115702479339,0.03305785123966945,7264051,887822
3/13/19,AKTX,224.2,180.952381,192.3809524,gnw,Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics‚Äôs Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA),"HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a...",https://www.globenewswire.com/news-release/2019/03/13/1752502/0/en/Positive-FDA-Meeting-Outlines-Path-Ahead-for-Akari-Therapeutics-s-Coversin-in-Hematopoietic-Stem-Cell-Transplant-Related-Thrombotic-Microangiopathy-HSCT-TMA.html,same,03/13/2019 08:30,0.175,0.0,0.05399999999999999,0.5574,0.0,0.9371,0.22727272727272727,0.009090909090909087,0.1856060606060606,-0.08333333333333333,2.1,5.9,1.8095238095238095,1.9238095238095234,81390887,362866
3/14/19,ATOS,368.2,52.04301075,58.92473118,gnw,Atossa Genetics Announces FDA Approval of Oral Endoxifen for ‚ÄúExpanded Access‚Äù as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient,"SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...",https://www.globenewswire.com/news-release/2019/03/14/1753171/0/en/Atossa-Genetics-Announces-FDA-Approval-of-Oral-Endoxifen-for-Expanded-Access-as-Post-Mastectomy-Treatment-for-a-U-S-Breast-Cancer-Patient.html,same,03/14/2019 08:30,-0.05299999999999999,0.179,-0.009000000000000008,-0.3182,0.6124,-0.6854,0.0,0.0,0.03557900432900433,-0.35294117647058826,4.65,7.07,0.5204301075268817,0.5892473118279568,92367779,6546315
3/22/19,LXRX,-21.9,-21.6182048,1.643489254,gnw,"Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes","THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday,...",https://www.globenewswire.com/news-release/2019/03/22/1759503/0/en/Lexicon-Pharmaceuticals-to-Host-Conference-Call-and-Webcast-Today-March-22-2019-to-Provide-a-Regulatory-Update-on-Sotagliflozin-in-Type-1-Diabetes.html,same,03/22/2019 14:16,0.0,0.0,0.041,0.0,0.0,0.296,0.0,0.13636363636363635,-0.1535123966942149,0.0,7.91,6.2,-0.2161820480404551,0.016434892541087105,3482386,806437
3/25/19,NK,32.5,21.01449275,35.47826087,bw,NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK‚Äôs Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy,"NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company‚Äôs Chairman & CEO, on March 21, 2019, exer...",http://www.businesswire.com/news/home/20190325005242/en/NantKwest-Chairman-CEO-Dr.-Patrick-Soon-Shiong-Exercises-39-Million-in-Warrants-and-Options-in-Support-of-NK%E2%80%99s-Natural-Killer-Cell-Strategic-Vision-Beyond-Check-Point-Immunotherapy,same,03/25/2019 08:00,0.087,-0.059999999999999984,0.02500000000000001,0.2263,-0.4215,0.2753,0.1,0.1,0.15999999999999995,0.2857142857142857,1.38,1.67,0.21014492753623193,0.3547826086956522,9016740,1620368
4/1/19,AVEO,35.3,38.75,43.75,bw,AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML,"AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO‚Äôs potent hepatocyte growth factor (HGF) inhibitory...",http://www.businesswire.com/news/home/20190401005861/en/AVEO-and-Biodesix-Announce-Positive-Results-from-Phase-Ib-Ficlatuzumab-Cytarabine-Trial-in-Patients-with-Relapsed-and-Refractory-AML,same,04/01/2019 16:05,0.353,0.098,-0.016,0.8668,0.3818,-0.8002,0.22727272727272727,0.5,0.08105392156862744,-0.2,8,11.1,0.38749999999999996,0.4375,3465468.1999999993,1400188
4/22/19,NVUS,-30,-27.91262136,0,bw,Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials,"Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced results from...",http://www.businesswire.com/news/home/20190422005248/en/Novus-Therapeutics-Announces-Results-of-Two-Single-Dose-OP0201-Phase-1-Clinical-Trials,same,04/22/2019 08:00,0.0,0.091,0.07500000000000001,0.0,0.3818,0.9891,0.0,0.0,0.2152380952380952,-0.25,74.16,53.46,-0.27912621359223294,0.0,17008.222222222226,33414
6/3/19,NK,25.2,25.24271845,33.98058252,bw,NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference,"NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jeffer...",http://www.businesswire.com/news/home/20190603005273/en/NantKwest-to-Present-and-Provide-Update-at-Upcoming-Jefferies-2019-Annual-Healthcare-Conference,same,06/03/2019 08:00,0.0,-0.059999999999999984,0.004,0.0,-0.4215,-0.128,0.0,0.1,0.22613636363636364,0.0,1.03,1.29,0.2524271844660194,0.3398058252427183,2348747,1620368
6/25/19,ACER,-78.6,-22.84644195,0,gnw,Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO‚Ñ¢ (celiprolol) in vEDS Patients,"NEWTON, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...",https://www.globenewswire.com/news-release/2019/06/25/1873784/0/en/Acer-Therapeutics-Receives-Complete-Response-Letter-from-U-S-FDA-for-use-of-EDSIVO-celiprolol-in-vEDS-Patients.html,same,06/25/2019 08:30,0.0,0.098,0.033,0.0,0.3818,0.6124,0.1,0.0,0.10126262626262626,0.0,5.34,4.12,-0.22846441947565538,0.0,5490955,274065
7/8/19,ADVM,22.5,22.53289474,23.02631579,gnw,Adverum Biotechnologies to Present Data at Upcoming Conferences,"MENLO PARK, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...",https://www.globenewswire.com/news-release/2019/07/08/1879380/32452/en/Adverum-Biotechnologies-to-Present-Data-at-Upcoming-Conferences.html,same,07/08/2019 07:58,0.0,0.0,0.037000000000000005,0.0,0.0,0.8442,0.0,0.15,0.06267857142857143,0.0,12.16,14.9,0.22532894736842107,0.2302631578947369,3888383,780579
7/24/19,PSTI,-25.1,-21.11111111,0,gnw,Pluristem Announces One-for-Ten Reverse Split of its Common Shares,"HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...",https://www.globenewswire.com/news-release/2019/07/24/1886961/11974/en/Pluristem-Announces-One-for-Ten-Reverse-Split-of-its-Common-Shares.html,same,07/24/2019 02:45,0.216,0.095,0.145,0.296,0.3182,0.9955,-0.3,0.0,-0.023501498501498505,-0.2857142857142857,5.4,4.26,-0.2111111111111112,0.0,413617.5999999999,299727
9/10/19,LXRX,21.1,22.85714286,25.71428571,gnw,Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting,"THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the...",https://www.globenewswire.com/news-release/2019/09/10/1913800/0/en/Lexicon-Pharmaceuticals-to-Present-Sotagliflozin-Clinical-Data-at-the-European-Association-for-the-Study-of-Diabetes-55th-Annual-Meeting.html,same,09/10/2019 16:01,0.0,0.0,0.028,0.0,0.0,0.2732,0.0,0.0,0.04545454545454545,0.0,1.4,1.72,0.22857142857142862,0.25714285714285723,4148433,806437
9/10/19,LXRX,21.1,22.85714286,25.71428571,gnw,Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi,"THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and...",https://www.globenewswire.com/news-release/2019/09/10/1913802/0/en/Lexicon-Pharmaceuticals-Announces-Termination-of-Alliance-and-Settlement-With-Sanofi.html,same,09/10/2019 16:01,0.0,0.0,0.058,0.0,0.0,0.9601,0.0,0.0,0.15514354066985644,0.09090909090909091,1.4,1.72,0.22857142857142862,0.25714285714285723,4148433,806437
9/23/19,PSTV,-49.5,-72.63513514,8.108108108,gnw,"Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering","AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering (the ‚ÄúOffering‚Äù) of 3,000,000...",https://www.globenewswire.com/news-release/2019/09/23/1919404/0/en/Plus-Therapeutics-Inc-Announces-Pricing-Of-15-Million-Underwritten-Public-Offering.html,same,09/23/2019 12:15,0.0,0.0,0.079,0.0,0.0,0.9913,0.0,0.0,-0.01148696264975335,-0.26666666666666666,14.8,4.05,-0.7263513513513513,0.08108108108108103,6930639,388899
9/23/19,PSTV,-49.5,-72.63513514,8.108108108,gnw,Plus Therapeutics to Receive $4.6MM Reimbursement Payment,"AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù) today announced that it received notice from the U.S. Department of Health and Human Services...",https://www.globenewswire.com/news-release/2019/09/23/1918967/0/en/Plus-Therapeutics-to-Receive-4-6MM-Reimbursement-Payment.html,same,09/23/2019 06:10,0.0,0.0,0.039,0.0,0.0,0.4588,0.0,0.0,0.0,0.0,14.8,4.05,-0.7263513513513513,0.08108108108108103,6930639,388899
9/25/19,TMDI,-42.7,-23.87096774,2.580645161,bw,Titan Medical Continues to Market Offering of Units,"Titan Medical Inc. (‚ÄúTitan‚Äù or the ‚ÄúCompany‚Äù) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in...",http://www.businesswire.com/news/home/20190924006063/en/Titan-Medical-Continues-to-Market-Offering-of-Units,prev,09/24/2019 17:00,0.0,0.094,0.051000000000000004,0.0,0.3818,0.8442,0.0,-0.03333333333333333,-0.032692307692307694,0.0,1.55,1.18,-0.2387096774193549,0.025806451612903247,1970516,3271909
10/2/19,SVRA,-58.5,-25.89928058,0,bw,Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program,"Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development prog...",http://www.businesswire.com/news/home/20191002005287/en/Savara-Announces-FDA-Response-From-Type-C-Meeting-on-Molgradex-for-aPAP-Development-Program,same,10/02/2019 08:02,0.0,0.0,0.009000000000000001,0.0,0.0,0.3798,0.0,0.0,0.08636363636363636,0.0,1.39,1.03,-0.2589928057553956,0.0,3704229,3185115
10/3/19,CBIO,24.6,21.17647059,23.1372549,gnw,Catalyst Biosciences Provides DalcA Phase 2b Trial Update,"SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a...",https://www.globenewswire.com/news-release/2019/10/03/1924663/35555/en/Catalyst-Biosciences-Provides-DalcA-Phase-2b-Trial-Update.html,same,10/03/2019 08:00,0.0,0.0,0.009000000000000001,0.0,0.0,0.4576,0.0,0.0,0.08696660482374768,-0.08333333333333333,5.1,6.18,0.21176470588235297,0.23137254901960796,915232,277130
10/7/19,SRNE,-25.5,-28.51405623,16.86746988,gnw,Sorrento Therapeutics Announces $25 Million Registered Direct Offering,"SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ‚ÄúSorrento‚Äù), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...",https://www.globenewswire.com/news-release/2019/10/07/1926068/0/en/Sorrento-Therapeutics-Announces-25-Million-Registered-Direct-Offering.html,same,10/07/2019 14:35,0.0,0.0,0.063,0.0,0.0,0.9652,0.1,0.13636363636363635,-0.06541068580542268,-0.09090909090909091,2.49,1.78,-0.28514056224899603,0.16867469879518068,11657507,8175771
11/13/19,DFFN,-54.7,-58.5,8.333333333,gnw,Diffusion Pharmaceuticals Announces $4.0 Million Public Offering,"CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (‚ÄúDiffusion‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biotechnology company developing new treatments...",https://www.globenewswire.com/news-release/2019/11/13/1946432/0/en/Diffusion-Pharmaceuticals-Announces-4-0-Million-Public-Offering.html,same,11/13/2019 09:34,0.0,0.0,0.067,0.0,0.0,0.9756,0.0,0.13636363636363635,-0.031682206682206684,-0.16666666666666666,0.6,0.249,-0.585,0.08333333333333341,6902034,1876817
11/18/19,NVIV,-37.5,-33.30864198,0,bw,InVivo Therapeutics Announces Proposed Public Offering of Common Stock,"InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offe...",http://www.businesswire.com/news/home/20191118005283/en/InVivo-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock,same,11/18/2019 08:15,0.0,0.201,0.08299999999999999,0.0,0.7003,0.9559,-0.15,-0.09999999999999999,-0.04942424242424243,-0.25,12.15,8.103,-0.33308641975308645,0.0,15093.066666666666,1293234
11/18/19,KRTX,443,195.3846154,207.6923077,bw,Karuna Therapeutics Announces Proposed Public Offering of Common Stock,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005866/en/Karuna-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock,same,11/18/2019 16:21,0.0,0.041999999999999996,0.038,0.0,0.0772,0.9602,-0.15,0.0,0.013497217068645642,-0.21052631578947367,32.5,96,1.9538461538461538,2.076923076923077,15010196,151509
11/18/19,KRTX,443,195.3846154,207.6923077,bw,Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005243/en/Karuna-Therapeutics-Announces-KarXT-Met-Primary-Endpoint-in-Phase-2-Clinical-Trial-of-Acute-Psychosis-in-Patients-with-Schizophrenia,same,11/18/2019 06:00,0.0,0.041999999999999996,0.05,0.0,0.0772,0.9888,0.5,0.0,0.05610364145658264,-0.26666666666666666,32.5,96,1.9538461538461538,2.076923076923077,15010196,151509
11/21/19,KRTX,-27.2,-21.67669989,0.661205961,bw,Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191120006025/en/Karuna-Therapeutics-Announces-Pricing-of-250-Million-Public-Offering-of-Common-Stock,prev,11/20/2019 18:58,0.0,0.041999999999999996,0.015000000000000006,0.0,0.0772,0.6602,-0.15,0.0,-0.01861672278338947,-0.05555555555555555,101.33,79.365,-0.216766998914438,0.006612059607223939,3143282,151509
11/21/19,ONTX,-45.7,-64.23580786,28.44978166,gnw,"Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering","NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (‚ÄúOnconova‚Äù), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...",https://www.globenewswire.com/news-release/2019/11/21/1950988/0/en/Onconova-Therapeutics-Inc-Announces-11-0-Million-Public-Offering.html,same,11/21/2019 11:23,0.0,0.087,0.064,0.0,0.3182,0.9709,0.0,0.0,-0.03991341991341993,-0.15384615384615385,0.458,0.1638,-0.6423580786026201,0.2844978165938865,38089826,9112162
11/25/19,SRNE,94.4,41.36363636,45,gnw,"Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal","SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, ""Sorrento"" or the ‚ÄúCompany‚Äù), confirmed today that on November 23, 2019, it received an unsolicited,...",https://www.globenewswire.com/news-release/2019/11/25/1951876/0/en/Sorrento-Therapeutics-Inc-Received-and-Rejected-Unsolicited-All-Cash-Acquisition-Proposal.html,same,11/25/2019 07:00,-0.248,0.0,0.08300000000000002,-0.5106,0.0,0.9529,0.0,0.4,0.27976190476190477,-0.14285714285714285,2.2,3.11,0.41363636363636347,0.44999999999999984,76411355,8175771
12/9/19,APTO,38.3,25.53191489,40.78014184,gnw,Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting,"SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (‚ÄúAptose‚Äù) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...",https://www.globenewswire.com/news-release/2019/12/09/1958050/35575/en/Aptose-Presents-New-Preclinical-CG-806-Data-at-the-2019-ASH-Annual-Meeting.html,same,12/09/2019 11:00,0.0,0.0,-0.005999999999999998,0.0,0.0,0.4854,0.13636363636363635,0.16,0.12385416666666667,0.08333333333333333,2.82,3.54,0.2553191489361703,0.40780141843971646,10192937,11282801
12/10/19,ITRM,21.9,21.25,79.75,gnw,Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections,"DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic...",https://www.globenewswire.com/news-release/2019/12/10/1958907/0/en/Iterum-Therapeutics-Announces-Topline-Results-from-Phase-3-Clinical-Trial-of-Oral-and-IV-Sulopenem-for-the-Treatment-of-Complicated-Intra-abdominal-Infections.html,same,12/10/2019 16:10,0.0,0.091,0.039,0.0,0.3818,0.9762,-0.5,0.0,0.058654729109274564,-0.4375,4,4.85,0.2124999999999999,0.7975000000000001,1577091,12365177
12/11/19,MRNS,38,31.85185185,36.2962963,gnw,Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement,"RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (‚ÄúMarinus‚Äù or the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering of 28,000,000...",https://www.globenewswire.com/news-release/2019/12/11/1959362/32077/en/Corrected-Press-Release-Marinus-Pharmaceuticals-Announces-Pricing-of-65-Million-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html,same,12/11/2019 10:30,0.0,0.0,0.08700000000000001,0.0,0.0,0.9927,-0.09999999999999999,0.0,-0.014984346011131734,-0.2857142857142857,5.4,7.12,0.3185185185185185,0.36296296296296293,3258794.5,211789
12/11/19,MRNS,38,31.85185185,36.2962963,gnw,Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement,"RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (‚ÄúMarinus‚Äù or the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering of 28,000,000...",https://www.globenewswire.com/news-release/2019/12/11/1959278/32077/en/Marinus-Pharmaceuticals-Announces-Pricing-of-65-Million-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html,same,12/11/2019 09:00,0.0,0.0,0.08700000000000001,0.0,0.0,0.9927,-0.09999999999999999,0.0,-0.014984346011131734,-0.2857142857142857,5.4,7.12,0.3185185185185185,0.36296296296296293,3258794.5,211789
12/16/19,MIRM,111,51.57894737,96.75438597,bw,Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the success...",http://www.businesswire.com/news/home/20191216005174/en/Mirum-Pharmaceuticals-Completes-Successful-Pre-NDA-Meeting-with-FDA-for-Maralixibat,same,12/16/2019 08:00,0.297,0.182,0.07,0.5859,0.5994,0.9798,0.75,0.3,0.1668261562998405,-0.15384615384615385,11.4,17.28,0.5157894736842106,0.9675438596491227,8450104,105530
12/23/19,IDRA,24.2,23.37662338,29.2987013,gnw,Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million,"EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional...",https://www.globenewswire.com/news-release/2019/12/23/1964133/33448/en/Idera-Pharmaceuticals-Announces-Private-Placement-Up-To-97-7-Million.html,same,12/23/2019 09:15,0.0,0.099,0.10300000000000001,0.0,0.4939,0.9922,0.0,0.0,-0.047619047619047616,-0.16666666666666666,1.54,1.9,0.23376623376623368,0.292987012987013,1799701,4234327
12/26/19,ACOR,43.2,40.30612245,41.83673469,bw,Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024,"Acorda Therapeutics, Inc. (Nasdaq: ACOR) (‚ÄúAcorda‚Äù or the ‚ÄúCompany‚Äù) today announced it has successfully completed its previously announced private exchange of $276 million aggregate principal amount...",http://www.businesswire.com/news/home/20191226005042/en/Acorda-Therapeutics-Completes-Exchange-of-276-Million-of-its-1.75-Convertible-Senior-Notes-due-June-2021-New-Convertible-Secured-Notes-Mature-December-2024,same,12/26/2019 07:00,0.208,0.113,0.128,0.6705,0.4939,0.9947,0.03712121212121212,0.19444444444444445,0.007359307359307353,-0.25,11.76,16.5,0.4030612244897959,0.41836734693877553,2099483,175238
12/27/19,MBOT,-20.7,-22.91666667,0.06875,gnw,Microbot Medical Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical...",https://www.globenewswire.com/news-release/2019/12/27/1964701/0/en/Microbot-Medical-Inc-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,same,12/27/2019 12:30,0.0,0.0,0.079,0.0,0.0,0.9805,0.05,0.0,-0.07661017843944674,-0.2,14.4,11.1,-0.2291666666666667,0.0006875000000000014,4293458,85367
12/27/19,MBOT,-20.7,-22.91666667,0.06875,gnw,Microbot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock,"HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase...",https://www.globenewswire.com/news-release/2019/12/27/1964668/0/en/Microbot-Medical-Inc-Announces-Closing-of-9-59-Million-Registered-Direct-Offering-of-Common-Stock.html,same,12/27/2019 10:00,0.0,0.075,0.074,0.0,0.296,0.964,-0.06666666666666667,-0.09333333333333334,-0.05535527690700105,-0.14285714285714285,14.4,11.1,-0.2291666666666667,0.0006875000000000014,4293458,85367
12/27/19,ITRM,95.5,74.63235294,137.8676471,gnw,Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection,"DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...",https://www.globenewswire.com/news-release/2019/12/26/1964576/0/en/Iterum-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-Clinical-Trial-of-Oral-Sulopenem-in-Uncomplicated-Urinary-Tract-Infection.html,prev,12/26/2019 17:00,0.0,0.094,0.032,0.0,0.3818,0.7964,0.0,0.0,0.12214646464646466,-0.14285714285714285,2.72,4.75,0.7463235294117646,1.378676470588235,10296615,12365177
12/31/19,ONTX,-20.1,-26.21845502,9.805432479,gnw,"Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market","NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (‚ÄúOnconova‚Äù or the ‚ÄúCompany‚Äù), a Phase 3-stage biopharmaceutical company discovering and developing novel...",https://www.globenewswire.com/news-release/2019/12/31/1965391/0/en/Onconova-Therapeutics-Inc-Announces-10-Million-Registered-Direct-Offering-Priced-At-The-Market.html,same,12/31/2019 11:30,0.0,0.0,0.06799999999999999,0.0,0.0,0.9759,0.1,0.0,-0.060173160173160184,-0.09090909090909091,0.5191,0.383,-0.26218455018300907,0.09805432479291071,70024993,9112162
1/13/20,AQST,-34,-23.37434095,0.527240773,gnw,Aquestive Therapeutics Receives FDA Response to Citizen‚Äôs Petition,"WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that...",https://www.globenewswire.com/news-release/2020/01/12/1969211/0/en/Aquestive-Therapeutics-Receives-FDA-Response-to-Citizen-s-Petition.html,prev,01/12/2020 18:16,0.0,0.102,0.095,0.0,0.3818,0.9933,0.0,0.0,0.1363113897596656,0.23076923076923078,5.69,4.36,-0.23374340949033393,0.005272407732864562,4037935,862715
1/14/20,NK,-27.9,-25.1908397,0.975572519,bw,NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein,"NantKwest Inc., (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced results from their Phase 1 trial investigating a novel, first-in-human immunotherapy cons...",http://www.businesswire.com/news/home/20200114005307/en/NantKwest-and-ImmunityBio-Announce-Complete-Response-in-Metastatic-Pancreatic-Cancer-in-the-First-Patient-to-Receive-PD-L1-Tumor-Targeted-Natural-Killer-Cells-PD-L1.t-haNK-Combined-with-N-803-IL-15-Fusion-Protein,same,01/14/2020 08:00,-0.17099999999999999,0.018000000000000016,-0.031000000000000014,-0.802,-0.128,-0.9885,0.15,0.1,0.07221428571428572,-0.24,6.55,4.9,-0.2519083969465648,0.00975572519083974,6387085,1620368
1/22/20,CNCE,33,30.24875622,30.24875622,bw,"Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata","Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/098,338 related to CTP-5...",http://www.businesswire.com/news/home/20200122005425/en/Concert-Pharmaceuticals-Announces-Notice-of-Allowance-for-U.S.-Patent-Application-Related-to-CTP-543-Lead-Candidate-for-Treatment-of-Alopecia-Areata,same,01/22/2020 08:40,0.0,-0.073,0.038000000000000006,0.0,-0.296,0.6808,0.0,0.0,0.19090909090909092,0.0,10.05,13.09,0.3024875621890546,0.3024875621890546,927844,420523
1/28/20,STSA,29.9,29.35500254,31.64042661,gnw,Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain,"SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results...",https://www.globenewswire.com/news-release/2020/01/28/1976390/0/en/Satsuma-Pharmaceuticals-Announces-Publication-of-STS101-Phase-1-Clinical-Trial-Results-in-HEADACHE-The-Journal-of-Head-and-Face-Pain.html,same,01/28/2020 16:05,-0.155,0.0,0.059,-0.5106,0.0,0.9493,0.0,0.0,0.20055555555555557,0.14285714285714285,19.69,25.47,0.29355002539360064,0.3164042661249365,68883,151645
2/18/20,BLPH,168.4,44.96062992,88.66141732,gnw,Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse¬Æ for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis,"WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (‚ÄúBellerophon‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biotherapeutics company, today announced positive...",https://www.globenewswire.com/news-release/2020/02/18/1986250/0/en/Bellerophon-Reports-Positive-Top-Line-Data-from-an-Ancillary-Acute-Hemodynamic-Study-of-INOpulse-for-Treatment-of-Pulmonary-Hypertension-Associated-with-Pulmonary-Fibrosis.html,same,02/18/2020 08:30,0.146,0.0,0.208,0.5574,0.0,0.9953,0.41363636363636364,0.22727272727272727,0.22821969696969693,0.0,6.35,9.205,0.44960629921259854,0.8866141732283467,23794023,83959
2/25/20,IMV,-40,-36.78414097,4.845814978,bw,"IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer","IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today reported updated results from DeCidE1, an ongoing Phase 2 study of its l...",http://www.businesswire.com/news/home/20200225005324/en/IMV-Inc.-Announces-Breakthrough-Data-from-DeCidE1-its-Ongoing-Phase-2-Study-of-DPX-Survivac-in-Patients-with-Advanced-Recurrent-Ovarian-Cancer,same,02/25/2020 03:05,-0.09799999999999999,0.081,0.013000000000000012,-0.5267,0.3182,-0.7522,0.4,0.0,0.15106806986117333,0.23076923076923078,4.54,2.87,-0.36784140969162993,0.04845814977973563,558727,183790
2/25/20,NMRD,76.3,72.56768819,151.1157394,bw,Nemaura Medical Plans Head-to-head Study with Major Glucose Monitoring System,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",http://www.businesswire.com/news/home/20200225005660/en/Nemaura-Medical-Plans-Head-to-head-Study-with-Major-Glucose-Monitoring-System,same,02/25/2020 09:17,0.0,0.106,0.078,0.0,0.3818,0.9864,0.03125,0.0,0.08677988677988677,0.23076923076923078,3.361,5.8,0.7256768818803926,1.5111573936328468,430946,87302
2/26/20,APM,-53.5,-31.28205128,0,bw,Aptorum Group Announces Pricing of $10 Million Registered Direct Offering,"Aptorum Group Limited (NASDAQ: APM) (‚ÄúAptorum Group‚Äù), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing o...",http://www.businesswire.com/news/home/20200226005498/en/Aptorum-Group-Announces-Pricing-of-10-Million-Registered-Direct-Offering,same,02/26/2020 09:15,0.0,0.097,0.09,0.0,0.4588,0.9896,0.1,-0.023809523809523808,0.009753143681715112,-0.07692307692307693,9.75,6.7,-0.3128205128205128,0.0,342649,226640
2/28/20,TNXP,-37.6,-23.94366197,2.112676056,gnw,"Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market","NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (‚ÄúTonix‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biopharmaceutical company, today announced it has entered into a...",https://www.globenewswire.com/news-release/2020/02/28/1992716/28908/en/Tonix-Pharmaceuticals-Inc-Prices-16-005-000-Common-Stock-Offering-Priced-At-The-Market.html,same,02/28/2020 08:45,0.0,0.0,0.08399999999999999,0.0,0.0,0.9633,-0.3,0.13636363636363635,0.006281565656565655,-0.125,1.42,1.08,-0.23943661971830976,0.021126760563380302,38786005,11637948
3/9/20,KALA,26.3,25.67353407,40.09508716,bw,Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS‚Ñ¢ for Signs and Symptoms of Dry Eye Disease,"Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announce...",http://www.businesswire.com/news/home/20200309005294/en/Kala-Pharmaceuticals-Announces-Statistically-Significant-Results-for-Primary-and-Key-Secondary-Endpoints-in-STRIDE-3-Clinical-Trial-Evaluating-EYSUVIS%E2%84%A2-for-Signs-and-Symptoms-of-Dry-Eye-Disease,same,03/09/2020 06:00,0.067,0.2,0.05399999999999999,0.2023,0.6705,0.9941,0.08166666666666668,0.5,0.16055194805194808,-0.05,6.31,7.93,0.2567353407290016,0.4009508716323297,7138132,2105682
3/12/20,TENX,-36.5,-34.65346535,0,bw,Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial,"Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...",http://www.businesswire.com/news/home/20200312005105/en/Tenax-Therapeutics-Completes-Enrollment-in-Phase-2-Pulmonary-Hypertension-Trial,same,03/12/2020 08:30,0.0,0.106,0.008,0.0,0.3818,0.6037,0.0,0.16,0.06002232142857145,-0.2608695652173913,1.01,0.66,-0.3465346534653465,0.0,311046,3746295
3/12/20,TENX,-36.5,-34.65346535,0,bw,Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market,"Tenax Therapeutics, Inc. (Nasdaq: TENX) (‚ÄúTenax‚Äù or the ‚ÄúCompany‚Äù), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and p...",http://www.businesswire.com/news/home/20200312005139/en/Tenax-Therapeutics-Announces-2.75-Million-Registered-Direct-Offering-Priced-At-the-Market,same,03/12/2020 08:00,0.0,0.102,0.097,0.0,0.3818,0.9926,0.1,0.0,-0.08351201989499862,-0.14285714285714285,1.01,0.66,-0.3465346534653465,0.0,311046,3746295
3/12/20,PSTV,-22.5,-22.53521127,0,gnw,Plus Therapeutics Welcomes Two New Directors,"AUSTIN, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù), today announced that Dr. Robert Lenk and Mr. Howard Clowes will join the Company‚Äôs Board of...",https://www.globenewswire.com/news-release/2020/03/12/1999378/0/en/Plus-Therapeutics-Welcomes-Two-New-Directors.html,same,03/12/2020 07:15,0.351,0.068,0.023,0.4019,0.296,0.6151,0.13636363636363635,0.0,0.05463944731068019,0.13793103448275862,1.42,1.1,-0.22535211267605623,0.0,124336,388899
3/18/20,ACER,-24.9,-24.9070632,1.617100372,gnw,Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA‚Äôs Office of New Drugs,"NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...",https://www.globenewswire.com/news-release/2020/03/18/2002958/0/en/Acer-Receives-Formal-Dispute-Resolution-Request-FDRR-Response-from-FDA-s-Office-of-New-Drugs.html,same,03/18/2020 16:05,-0.172,0.098,0.06199999999999999,-0.4019,0.3818,0.912,0.13636363636363635,0.0,0.10817099567099565,0.0,2.69,2.02,-0.2490706319702602,0.01617100371747207,69597,274065
3/19/20,RCKT,32.9,30.96446701,31.37055838,bw,Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the...",http://www.businesswire.com/news/home/20200319005055/en/Rocket-Pharmaceuticals-Announces-Science-Translational-Medicine-Publication-of-its-Program-in-Danon-Disease,same,03/19/2020 07:00,0.0,0.0,0.020000000000000004,0.0,0.0,0.791,0.0,0.3,0.0775045568466621,-0.10526315789473684,9.85,12.9,0.3096446700507615,0.31370558375634516,779502,534683
3/19/20,BLU,25.2,25.78125,30.234375,bw,BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough,"BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the ‚ÄúCompany‚Äù or ‚ÄúBELLUS Health‚Äù), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hyper...",http://www.businesswire.com/news/home/20200319005092/en/BELLUS-Health-Announces-Completion-of-Enrollment-in-Phase-2-RELIEF-Trial-of-BLU-5937-for-the-Treatment-of-Refractory-Chronic-Cough,same,03/19/2020 07:00,0.176,0.087,0.12499999999999999,0.5904,0.3182,0.9838,0.0,-0.125,0.08903846153846152,-0.125,6.4,8.05,0.25781250000000006,0.3023437500000001,721224,728746
3/24/20,BXRX,-48.1,-24.08026756,0,gnw,Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants,"MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (‚ÄúBaudax‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...",https://www.globenewswire.com/news-release/2020/03/24/2005589/0/en/Baudax-Bio-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Warrants.html,same,03/24/2020 09:15,0.0,0.188,0.08299999999999999,0.0,0.7003,0.9854,-0.15,0.6,-0.002639678030303027,-0.16666666666666666,2.99,2.27,-0.24080267558528434,0.0,4315851,1454542
3/24/20,IMAC,1025.2,147.5,147.5,gnw,IMAC Launches New Telehealth Options to Maintain Consistent Communications with Active Care Patients Choosing to ‚ÄúShelter in Place‚Äù,"BRENTWOOD, Tenn, March 24, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the ‚ÄúCompany‚Äù or ‚ÄúIMAC‚Äù), a provider of innovative medical advancements and care specializing in regenerative...",https://www.globenewswire.com/news-release/2020/03/24/2005464/0/en/IMAC-Launches-New-Telehealth-Options-to-Maintain-Consistent-Communications-with-Active-Care-Patients-Choosing-to-Shelter-in-Place.html,same,03/24/2020 08:00,0.269,0.196,0.08199999999999999,0.7096,0.7269,0.9936,0.08434343434343435,0.25,0.07869264069264068,-0.041666666666666664,2,4.95,1.475,1.475,32046564,527707
3/24/20,CAPR,51.7,43.08943089,76.42276423,gnw,Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development,"LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...",https://www.globenewswire.com/news-release/2020/03/24/2005458/0/en/Capricor-Therapeutics-to-Host-a-Key-Opinion-Leader-Call-On-Why-Exosomes-are-Uniquely-Suited-for-Vaccine-Development.html,same,03/24/2020 08:00,0.0,0.102,0.033,0.0,0.3818,0.5719,0.1875,0.0,0.09829545454545455,0.25,1.23,1.76,0.43089430894308944,0.7642276422764227,13083827,201222
3/30/20,EYES,-51.3,-49.55752212,11.97345133,bw,"Second Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO","Second Sight Medical Products, Inc. (NASDAQ: EYES) (‚ÄúSecond Sight‚Äù or the ‚ÄúCompany‚Äù), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial...",http://www.businesswire.com/news/home/20200330005581/en/Second-Sight-Announces-Employee-Layoffs-Intent-to-Wind-Down-Operations-and-Appointment-of-Matthew-Pfeffer-as-Acting-CEO,same,03/30/2020 13:15,0.0,0.075,0.027000000000000003,0.0,0.2732,0.6705,-0.051851851851851864,-0.15,0.021399176954732507,-0.14285714285714285,2.26,1.14,-0.49557522123893805,0.11973451327433647,1131077,6372472
3/30/20,STIM,28.3,25.92592593,40.7345679,gnw,Neuronetics Recognized as 2020 Top Neurology Device Provider,"Company acknowledged on Top 10 List by MedTech Outlook Magazine MALVERN, Pa., March 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company...",https://www.globenewswire.com/news-release/2020/03/30/2008259/0/en/Neuronetics-Recognized-as-2020-Top-Neurology-Device-Provider.html,same,03/30/2020 07:30,0.205,0.065,0.068,0.2023,0.2023,0.9657,0.5,0.16666666666666666,0.2621323529411765,-0.14285714285714285,1.62,2.04,0.2592592592592592,0.4073456790123456,1654461,352165
3/31/20,SGBX,351.5,144.7368421,156.3157895,bw,"SG Blocks, Inc. and Transcend Onsite Care and Execute a Memorandum of Understanding","SG Blocks, Inc. (Nasdaq: SGBX) (‚ÄúSG Blocks‚Äù or the ‚ÄúCompany‚Äù), and Transcend Onsite Care, a cutting edge provider of on-site point of contact medical care, have executed a Memorandum of Understanding...",http://www.businesswire.com/news/home/20200331005238/en/SG-Blocks-Inc.-and-Transcend-Onsite-Care-and-Execute-a-Memorandum-of-Understanding,same,03/31/2020 08:15,0.086,0.086,0.10400000000000001,0.3182,0.6124,0.9914,0.0,-0.3,0.04151785714285715,0.23076923076923078,3.8,9.3,1.4473684210526319,1.5631578947368423,21426357,989419
4/7/20,MOTS,28.3,20.16923077,30.75384615,gnw,Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its GEN2 Pure-Vu¬Æ System in Israel,"FORT LAUDERDALE, Fla., April 07, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (""Motus GI"" or the ""Company""), a medical technology company providing endoscopy solutions that...",https://www.globenewswire.com/news-release/2020/04/07/2012878/0/en/Motus-GI-Receives-Approval-from-the-Israeli-Ministry-of-Health-to-Initiate-Commercial-Sales-of-its-GEN2-Pure-Vu-System-in-Israel.html,same,04/07/2020 09:00,0.134,0.061,0.11500000000000002,0.4767,0.1779,0.9908,0.0,0.0,0.08933150183150183,-0.2727272727272727,0.65,0.7811,0.20169230769230767,0.3075384615384615,733112,1319258
4/8/20,MRSN,21.6,28.02721088,35.91836735,gnw,Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility,"CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...",https://www.globenewswire.com/news-release/2020/04/08/2013249/0/en/Mersana-Therapeutics-Raises-65-Million-in-Gross-Proceeds-Through-its-At-the-Market-Facility.html,prev,04/07/2020 22:07,-0.22,0.106,0.064,-0.4767,0.3818,0.9565,0.0,0.0,-0.010599999999999997,-0.1111111111111111,7.35,9.41,0.2802721088435375,0.35918367346938784,7542454,748706
4/29/20,CAPR,252.7,64.09266409,113.8996139,gnw,New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002,"LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (‚ÄúCapricor‚Äù) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological...",https://www.globenewswire.com/news-release/2020/04/29/2024283/0/en/New-Capricor-Data-Reports-100-Percent-Survival-in-Critical-COVID-19-Patients-Treated-with-CAP-1002.html,same,04/29/2020 09:15,-0.15,0.106,0.051000000000000004,-0.3182,0.3818,0.9774,0.06818181818181818,0.0,0.034866522366522365,-0.2916666666666667,5.18,8.5,0.640926640926641,1.1389961389961392,199350507,201222
4/29/20,AVEO,25.6,21.4953271,22.6635514,bw,AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program,"AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO‚Äôs vascular endothelial growth factor receptor tyro...",http://www.businesswire.com/news/home/20200429005779/en/AVEO-Oncology-to-Present-Final-Overall-Survival-Analysis-from-the-Phase-3-TIVO-3-Trial-of-Tivozanib-in-Renal-Cell-Carcinoma-at-the-ASCO-2020-Virtual-Scientific-Program,same,04/29/2020 14:30,0.0,0.091,-0.033999999999999996,0.0,0.3818,-0.8271,0.0,0.16666666666666666,0.09545454545454546,0.0,4.28,5.2,0.21495327102803735,0.22663551401869153,887716,1400188
4/29/20,TXMD,78,54.38596491,61.42105263,bw,TherapeuticsMD Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA¬Æ,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women‚Äôs healthcare company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent that covers the labeled in...",http://www.businesswire.com/news/home/20200429005171/en/TherapeuticsMD-Announces-Issuance-of-First-Orange-Book-Listable-U.S.-Patent-for-ANNOVERA%C2%AE,same,04/29/2020 06:50,0.0,0.18,0.097,0.0,0.6908,0.9393,0.25,0.5,0.1837662337662338,0.0,1.14,1.76,0.5438596491228072,0.6142105263157897,25867495,8619757
5/6/20,VAPO,34.5,23.71134021,27.09278351,bw,Vapotherm Announces Proposed Public Offering of Common Stock,"Vapotherm, Inc. (NYSE:VAPO) (‚ÄúVapotherm‚Äù), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI¬Æ Technology products that are used to treat pa...",http://www.businesswire.com/news/home/20200506006032/en/Vapotherm-Announces-Proposed-Public-Offering-of-Common-Stock,same,05/06/2020 16:08,0.0,0.181,0.078,0.0,0.6486,0.967,-0.15,0.0,0.05238095238095238,-0.18181818181818182,24.25,30,0.23711340206185566,0.2709278350515464,2255528,259588
5/15/20,SEEL,31.1,22.78481013,25.3164557,gnw,Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors,"NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...",https://www.globenewswire.com/news-release/2020/05/15/2034331/14295/en/Seelos-Therapeutics-Announces-Appointment-of-Judith-Dunn-to-the-Board-of-Directors.html,same,05/15/2020 10:30,0.0,0.018000000000000002,0.027000000000000003,0.0,0.128,0.8442,0.0,0.06818181818181818,0.05179425837320574,0.16666666666666666,0.79,0.97,0.2278481012658227,0.2531645569620252,7644008,6143779
5/15/20,SEEL,31.1,22.78481013,25.3164557,gnw,Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome,"NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...",https://www.globenewswire.com/news-release/2020/05/15/2034166/14295/en/Seelos-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-for-SLS-005-Trehalose-in-Sanfilippo-Syndrome.html,same,05/15/2020 07:30,0.0,0.018000000000000002,0.14200000000000002,0.0,0.128,0.9246,0.3,0.06818181818181818,0.17337662337662338,0.0,0.79,0.97,0.2278481012658227,0.2531645569620252,7644008,6143779
5/20/20,ATOS,25.7,25,52.27272727,gnw,Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture,"SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...",https://www.globenewswire.com/news-release/2020/05/20/2036465/0/en/Atossa-Therapeutics-Announces-Successful-In-vitro-Testing-Results-of-COVID-19-Drug-AT-H201-Inhibits-SARS-CoV-2-Infectivity-of-VERO-Cells-in-Laboratory-Culture.html,same,05/20/2020 09:30,0.077,0.108,0.07500000000000001,0.4404,0.4404,0.9549,0.75,0.5,0.2916666666666667,-0.1,1.76,2.2,0.2500000000000001,0.5227272727272728,8792662,6546315
5/22/20,XERS,28,26.08695652,27.17391304,bw,Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formul...",http://www.businesswire.com/news/home/20200522005045/en/Xeris-Pharmaceuticals-Announces-Positive-Findings-From-the-Outpatient-Portion-of-a-Phase-2-Proof-of-Concept-Study-of-Its-Developmental-Ready-to-Use-RTU-Glucagon-in-Patients-at-Risk-of-Postprandial-Hypoglycemia-Following-Bariatric-Surgery,same,05/22/2020 08:00,0.046,0.095,0.026000000000000002,0.3612,0.3182,0.963,0.11363636363636363,0.0,0.1321126547870734,-0.5,4.6,5.8,0.26086956521739135,0.27173913043478265,1740201,2004997
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering,"Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i...",http://www.businesswire.com/news/home/20200526005915/en/Atara-Biotherapeutics-Announces-Pricing-of-175.5-Million-Public-Offering,same,05/27/2020 01:16,0.0,-0.010999999999999996,0.075,0.0,-0.0772,0.9806,0.0,0.0,-0.04216248867411658,0.0,15.59,11.32,-0.2738935214881334,0.01154586273252083,4835142,996792
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants,"Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i...",http://www.businesswire.com/news/home/20200526005809/en/Atara-Biotherapeutics-Announces-Proposed-Offering-of-Common-Stock-and-Pre-Funded-Warrants,same,05/26/2020 16:05,0.0,-0.010999999999999996,0.085,0.0,-0.0772,0.9862,-0.3,0.0,-0.03832488649561822,-0.16666666666666666,15.59,11.32,-0.2738935214881334,0.01154586273252083,4835142,996792
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including sol...",http://www.businesswire.com/news/home/20200526005266/en/Atara-Biotherapeutics-Presents-Data-Demonstrating-Safety-Sustained-Disability-Improvement-at-12-Months-with-ATA188-in-Patients-with-Progressive-Multiple-Sclerosis-in-Late-Breaking-e-Poster-at-the-2020-European-Academy-of-Neurology-Virtual-Congress,same,05/26/2020 07:00,0.162,-0.009999999999999995,0.069,0.7003,-0.0772,0.9978,0.0,0.0,0.1536943282705995,-0.061224489795918366,15.59,11.32,-0.2738935214881334,0.01154586273252083,4835142,996792
5/27/20,NK,39.1,37.56805808,51.36116153,bw,"ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‚ÄòOperation Warp Speed‚Äô to Develop Novel Adenovirus COVID-19 Vaccine ","NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected t...",http://www.businesswire.com/news/home/20200527005680/en/ImmunityBio-NantKwest-Sign-COVID-19-Joint-Development-Manufacturing-and-Marketing-Agreement-ImmunityBio-Selected-for-%E2%80%98Operation-Warp-Speed%E2%80%99-to-Develop-Novel-Adenovirus-COVID-19-Vaccine%C2%A0,same,05/27/2020 12:00,0.216,-0.067,0.08,0.6705,-0.4215,0.9966,0.0,0.1,0.13129503560955172,-0.10526315789473684,5.51,7.58,0.3756805807622505,0.5136116152450091,22465025,1620368
6/4/20,TMDI,467.1,130.8823529,130.8823529,bw,Titan Medical Announces Development and License Agreements With Medtronic and Senior Secured Loan,"Titan Medical Inc. (‚ÄúTitan‚Äù or ‚ÄúTitan Medical‚Äù) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that i...",http://www.businesswire.com/news/home/20200604005323/en/Titan-Medical-Announces-Development-and-License-Agreements-With-Medtronic-and-Senior-Secured-Loan,same,06/04/2020 07:30,0.304,0.088,0.176,0.5859,0.3818,0.9986,0.0,-0.03333333333333333,0.09690048323769254,0.045454545454545456,0.68,1.57,1.3088235294117647,1.3088235294117647,91459985,3271909
6/15/20,CLDX,37.3,45.31886024,50.74626866,gnw,Celldex Therapeutics Announces Proposed Public Offering of Common Stock,"HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (‚ÄúCelldex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market...",https://www.globenewswire.com/news-release/2020/06/15/2048347/24180/en/Celldex-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html,same,06/15/2020 16:01,0.0,0.0,0.06599999999999999,0.0,0.0,0.9607,-0.15,-0.16666666666666666,-0.031793743890518096,-0.2,7.37,10.71,0.4531886024423339,0.5074626865671641,7718715,931400
6/25/20,EKSO,135.3,31.20503597,57.55395684,gnw,Ekso Bionics¬Æ Receives FDA Clearance to Market its EksoNR‚Ñ¢ Robotic Exoskeleton for Use with Acquired Brain Injury Patients,"RICHMOND, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ‚ÄúCompany‚Äù), an industry leader in exoskeleton technology for medical and industrial use, today...",https://www.globenewswire.com/news-release/2020/06/25/2053400/29945/en/Ekso-Bionics-Receives-FDA-Clearance-to-Market-its-EksoNR-Robotic-Exoskeleton-for-Use-with-Acquired-Brain-Injury-Patients.html,same,06/25/2020 08:30,-0.141,0.0,-0.0010000000000000009,-0.4215,0.0,-0.2815,-0.1,0.0,0.19329710144927534,-0.2857142857142857,5.56,7.295,0.3120503597122303,0.5755395683453238,123616682,501993
7/27/20,VTVT,27.9,21.13821138,25.6097561,gnw,vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference,"HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International...",https://www.globenewswire.com/news-release/2020/07/27/2067814/0/en/vTv-Therapeutics-to-Present-Additional-Clinical-Data-from-the-STEADFAST-Study-of-Azeliragon-at-the-Virtual-Alzheimer-s-Association-International-Conference.html,same,07/27/2020 07:30,0.126,0.0,0.104,0.4084,0.0,0.9719,0.13333333333333333,0.05333333333333334,0.08573365231259968,0.0,2.46,2.98,0.21138211382113822,0.2560975609756097,7210399,14212883
8/4/20,PRPO,25.2,29.73856209,63.39869281,gnw,Precipio Launches Covid-19 Antibody Test in its CLIA laboratory,"NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has completed the internal validation of the FDA-approved COVID-19...",https://www.globenewswire.com/news-release/2020/08/04/2072650/0/en/Precipio-Launches-Covid-19-Antibody-Test-in-its-CLIA-laboratory.html,same,08/04/2020 10:45,0.0,0.0,0.063,0.0,0.0,0.9509,0.0,0.06818181818181818,0.024905303030303028,-0.09090909090909091,3.06,3.97,0.29738562091503273,0.6339869281045751,28731003,359477
8/13/20,MBOT,20.8,20.57488654,23.14674735,gnw,Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System,"HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT),...",https://www.globenewswire.com/news-release/2020/08/13/2077955/0/en/Microbot-Medical-to-Share-Current-Results-of-a-Feasibility-Animal-Study-Utilizing-the-LIBERTY-Robotic-System.html,same,08/13/2020 09:00,0.328,0.0,0.08099999999999999,0.7456,0.0,0.9493,-0.03333333333333333,0.0,0.03823529411764707,0.14285714285714285,6.61,7.97,0.20574886535552184,0.2314674735249622,1519708,85367
8/17/20,CKPT,21.1,20.53140097,22.22222222,gnw,"Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020","NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (‚ÄúCheckpoint‚Äù) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....",https://www.globenewswire.com/news-release/2020/08/17/2079189/36989/en/Checkpoint-Therapeutics-to-Present-at-Virtual-Corporate-Access-Summit-Hosted-by-B-Riley-FBR-on-Wednesday-August-19-2020.html,same,08/17/2020 08:00,0.0,0.0,-0.005999999999999998,0.0,0.0,-0.3818,0.0,0.13636363636363635,0.05151515151515152,0.0,2.07,2.495,0.20531400966183588,0.2222222222222222,904990,737628
8/24/20,ODT,-45.3,-25.21419829,1.754385965,bw,"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",http://www.businesswire.com/news/home/20200824005197/en/Odonate-Therapeutics-Announces-Positive-Top-line-Results-from-CONTESSA-a-Phase-3-Study-of-Tesetaxel-in-Patients-with-Metastatic-Breast-Cancer,same,08/24/2020 07:30,-0.033,0.095,-0.011999999999999997,-0.2023,0.296,-0.9375,0.22727272727272727,0.0,0.06427042160737813,-0.16666666666666666,24.51,18.33,-0.2521419828641372,0.017543859649122796,3378618,10678979
9/28/20,ABEO,-41.4,-24.82758621,0.689655172,gnw,Abeona Therapeutics Announces Leadership and Board Transitions,"NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive...",https://www.globenewswire.com/news-release/2020/09/28/2099961/0/en/Abeona-Therapeutics-Announces-Leadership-and-Board-Transitions.html,same,09/28/2020 09:27,0.0,0.0,-0.007000000000000006,0.0,0.0,-0.128,0.0,0.13636363636363635,0.14124579124579123,-0.2857142857142857,1.45,1.09,-0.24827586206896543,0.006896551724137937,13854882,1436088
10/20/20,ALRN,31.6,27.93296089,37.98882682,gnw,Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium,"WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b...",https://www.globenewswire.com/news-release/2020/10/20/2111157/28652/en/Aileron-Therapeutics-to-Host-Conference-Call-to-Discuss-Results-from-Phase-1b-Proof-of-Concept-Study-of-Chemoprotective-Therapy-ALRN-6924-Being-Presented-at-EORTC-NCI-AACR-Annual-S.html,same,10/20/2020 09:24,0.0,0.0,-0.009999999999999995,0.0,0.0,-0.5286,0.0,0.13636363636363635,0.11717171717171715,0.0,1.79,2.29,0.27932960893854747,0.3798882681564247,5059270,1133962
11/6/20,ASMB,-69.4,-22.6984127,0.793650794,gnw,Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...",https://www.globenewswire.com/news-release/2020/11/06/2122215/16259/en/Assembly-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,same,11/06/2020 16:30,0.217,0.121,0.156,0.3612,0.4404,0.9882,0.0,0.5,0.05307668521954236,-0.14285714285714285,6.3,4.87,-0.22698412698412695,0.007936507936507908,21650297,728882
12/9/20,RCKT,83.4,28.25327511,39.62882096,bw,Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",http://www.businesswire.com/news/home/20201209005516/en/Rocket-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock,same,12/09/2020 07:51,0.0,0.0,0.087,0.0,0.0,0.9858,-0.15,0.3,0.04525904203323557,-0.18181818181818182,45.8,58.74,0.28253275109170317,0.3962882096069871,8365285,534683
12/15/20,SRTS,25.7,26.76056338,26.76056338,gnw,Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100‚Ñ¢ Systems,"BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and...",https://www.globenewswire.com/news-release/2020/12/15/2145317/0/en/Sensus-Healthcare-Engages-Ekpac-Healthcare-Ltd-as-New-Exclusive-Distributor-in-China-for-SRT-100-Systems.html,same,12/15/2020 08:00,0.212,0.129,0.16199999999999998,0.3612,0.5256,0.9952,0.13636363636363635,0.3,0.2287056277056277,0.35714285714285715,3.55,4.5,0.267605633802817,0.267605633802817,128530,36153
12/17/20,ATXI,47.7,39.03061225,59.43877551,gnw,Avenue Therapeutics Provides Regulatory Update for IV Tramadol,"NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a...",https://www.globenewswire.com/news-release/2020/12/17/2146835/0/en/Avenue-Therapeutics-Provides-Regulatory-Update-for-IV-Tramadol.html,same,12/17/2020 07:00,0.0,0.082,0.021,0.0,0.3818,0.3818,0.0,0.13636363636363635,0.04128787878787878,0.0,3.92,5.45,0.39030612244897966,0.5943877551020409,9815206,599895
12/21/20,NK,56.1,23.09820194,36.6989396,bw,"ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agree...",http://www.businesswire.com/news/home/20201221005280/en/ImmunityBio-and-NantKwest-to-Merge-Creating-a-Leading-Immunotherapy-and-Cell-Therapy-Company,same,12/21/2020 06:05,0.167,-0.065,0.051000000000000004,0.296,-0.4215,0.9897,0.0,0.1,0.09448629148629148,0.05172413793103448,13.014,16.02,0.23098201936376214,0.3669893960350392,37616708,1620368
1/4/21,EYPT,36.9,30.57971015,35.67391304,gnw,EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics,"WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic...",https://www.globenewswire.com/news-release/2021/01/04/2152262/0/en/EyePoint-Pharmaceuticals-Announces-15-7-Million-Equity-Investment-by-Asia-Partner-Ocumension-Therapeutics.html,prev,01/03/2021 19:00,0.0,0.2,0.108,0.0,0.6124,0.9893,0.0,0.5,0.041148554510623464,0.0,6.9,9.01,0.30579710144927524,0.35673913043478245,1314861,229473
1/8/21,APDN,104.9,103.8528897,116.2854641,bw,U.S. FDA Lists Applied DNA‚Äôs Linea‚Ñ¢ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7),"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the ‚ÄúCompany‚Äù), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) publish...",http://www.businesswire.com/news/home/20210108005522/en/U.S.-FDA-Lists-Applied-DNA%E2%80%99s-Linea%E2%84%A2-COVID-19-Assay-Kit-as-1-of-Only-2-EUA-Authorized-Tests-Able-to-Detect-S-Gene-Mutation-Found-in-SARS-CoV-2-U.K.-Variant-B.1.1.7,same,01/08/2021 13:43,0.0,0.0,0.054,0.0,0.0,0.9665,0.25,0.0,0.10311942959001785,-0.07142857142857142,5.71,11.64,1.0385288966725046,1.1628546409807357,22046212,774964
1/11/21,DFFN,34,31.31313131,36.36363636,gnw,Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference,"CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (‚ÄúDiffusion‚Äù or ‚Äúthe Company‚Äù), today announced that the Company is participating in the...",https://www.globenewswire.com/news-release/2021/01/11/2156163/0/en/Diffusion-Pharmaceuticals-to-Participate-in-H-C-Wainwright-BioConnect-2021-Conference.html,same,01/11/2021 07:30,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.99,1.3,0.3131313131313132,0.36363636363636376,18235000,1876817
1/14/21,LXRX,105.4,90.75829384,122.7488152,gnw,Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure,"THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback...",https://www.globenewswire.com/news-release/2021/01/14/2158603/0/en/Lexicon-Pharmaceuticals-Provides-Regulatory-Update-on-Sotagliflozin-in-Heart-Failure.html,same,01/14/2021 08:00,-0.268,0.0,-0.10300000000000001,-0.5106,0.0,-0.9712,-0.3166666666666667,0.0,-0.06074810606060608,-0.3333333333333333,4.22,8.05,0.9075829383886259,1.227488151658768,163685746,806437
1/19/21,ACRS,220.2,34.02135231,41.99288256,gnw,Aclaris Announces Proposed Public Offering of Common Stock,"WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...",https://www.globenewswire.com/news-release/2021/01/19/2161003/37216/en/Aclaris-Announces-Proposed-Public-Offering-of-Common-Stock.html,same,01/19/2021 16:01,0.0,0.189,0.072,0.0,0.5994,0.9729,-0.15,0.0,-0.023106060606060623,-0.18181818181818182,14.05,18.83,0.3402135231316724,0.41992882562277567,114362153,715924
1/20/21,TLSA,49.2,35.14285714,51.14285714,gnw,"Tiziana Life Sciences plc (""Tiziana"" or the ""Company"") - AIM Delisting and Admission to the Standard Listing Segment of Main Market","NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (‚ÄúTiziana‚Äù or the ‚ÄúCompany‚Äù), a biotechnology company focused on innovative therapeutics...",https://www.globenewswire.com/news-release/2021/01/20/2161151/0/en/Tiziana-Life-Sciences-plc-Tiziana-or-the-Company-AIM-Delisting-and-Admission-to-the-Standard-Listing-Segment-of-Main-Market.html,same,01/20/2021 02:00,0.0,0.175,0.154,0.0,0.6705,0.9758,0.08333333333333333,0.3181818181818182,0.054099821746880564,0.3333333333333333,3.5,4.73,0.35142857142857153,0.5114285714285715,19709055,635779
1/20/21,ADMP,77.6,39.10505837,61.47859922,gnw,Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19,"SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (‚ÄúAdamis‚Äù) announced today the submission of an Investigational New Drug (IND) to FDA for the...",https://www.globenewswire.com/news-release/2021/01/20/2161463/32832/en/Adamis-Pharmaceuticals-Announces-IND-Submission-to-FDA-for-Tempol-for-the-Treatment-of-COVID-19.html,same,01/20/2021 09:00,0.0,0.0,-0.012000000000000004,0.0,0.0,-0.3095,0.0,0.13636363636363635,0.1766969696969697,-0.125,1.028,1.43,0.39105058365758744,0.6147859922178988,277533141,2727524
1/21/21,DYN,-25.6,-20.18038332,0.601277715,gnw,Dyne Therapeutics Announces Pricing of $168 Million Public Offering,"WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...",https://www.globenewswire.com/news-release/2021/01/21/2161815/0/en/Dyne-Therapeutics-Announces-Pricing-of-168-Million-Public-Offering.html,prev,01/20/2021 20:05,0.0,0.193,0.08399999999999999,0.0,0.6705,0.9786,0.0,0.5,0.007435465768799106,-0.09090909090909091,26.61,21.24,-0.2018038331454341,0.00601277715144683,4131600,266420
1/21/21,ADTX,45.6,22.65582131,117.2299151,gnw,AditxtScore‚Ñ¢ Immune Monitoring Service Will be Operational on February 1st,"Company Plans to Offer Service through Channel Partners Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the ‚ÄúCompany‚Äù) (Nasdaq: ADTX),...",https://www.globenewswire.com/news-release/2021/01/21/2162117/0/en/AditxtScore-Immune-Monitoring-Service-Will-be-Operational-on-February-1st.html,same,01/21/2021 08:00,0.196,0.0,0.095,0.296,0.0,0.975,0.0,0.0,0.07053571428571428,0.1,3.0981,3.8,0.2265582130983505,1.1722991510926053,138385085,281270
2/1/21,APLT,21.3,22.99128751,37.99612778,gnw,Applied Therapeutics Announces Restart of Pediatric Galactosemia Study,"FDA Clinical Hold Lifted NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug...",https://www.globenewswire.com/news-release/2021/02/01/2167143/0/en/Applied-Therapeutics-Announces-Restart-of-Pediatric-Galactosemia-Study.html,same,02/01/2021 07:00,0.0,0.087,0.13899999999999998,0.0,0.3182,0.9895,0.0,0.13636363636363635,0.10237631416202844,0.3,20.66,25.41,0.22991287512100678,0.37996127783155864,395194,74181
2/8/21,SIEN,36.6,33.51157156,49.21881527,gnw,Sientra Commences Public Offering of Common Stock,"SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (‚ÄúSientra‚Äù or the ‚ÄúCompany‚Äù), a medical aesthetics company uniquely focused on plastic surgeons, today announced...",https://www.globenewswire.com/news-release/2021/02/08/2171689/33599/en/Sientra-Commences-Public-Offering-of-Common-Stock.html,same,02/08/2021 16:01,0.0,0.091,0.077,0.0,0.3818,0.9686,-0.15,0.1875,-0.0036666666666666636,-0.3,5.9845,7.99,0.3351157155986299,0.49218815272788036,7375792,868149
2/9/21,RMTI,30.4,26.97368421,30.2631579,gnw,Rockwell Medical Announces U.S. Availability of Triferic¬Æ AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis,"WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...",https://www.globenewswire.com/news-release/2021/02/09/2172048/30312/en/Rockwell-Medical-Announces-U-S-Availability-of-Triferic-AVNU-for-Replacement-of-Iron-and-Maintenance-of-Hemoglobin-in-Patients-on-Hemodialysis.html,same,02/09/2021 07:00,0.0,0.107,0.09699999999999999,0.0,0.4588,0.9828,0.0,0.0,0.16587301587301587,0.09090909090909091,1.52,1.93,0.2697368421052631,0.3026315789473684,13405903,1285539
2/10/21,ITRM,20.3,24.65753425,27.85388128,gnw,Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules,"DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...",https://www.globenewswire.com/news-release/2021/02/10/2172766/0/en/Iterum-Therapeutics-plc-Announces-35-0-Million-Registered-Direct-Offering-of-Ordinary-Shares-Priced-At-the-Market-under-Nasdaq-Rules.html,prev,02/09/2021 23:58,0.121,0.098,0.082,0.296,0.3818,0.9821,-0.075,0.0,-0.004968805704099822,-0.4,2.19,2.73,0.24657534246575344,0.27853881278538806,142802937,12365177
2/16/21,PAVM,28.3,23.35164835,31.04395604,gnw,First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed‚Äôs CarpX¬Æ Device,"NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ‚ÄúCompany‚Äù or ‚ÄúPAVmed‚Äù), a highly differentiated, multi-product, commercial-stage medical technology company, today...",https://www.globenewswire.com/news-release/2021/02/16/2176335/0/en/First-U-S-Patient-Undergoes-Successful-Minimally-Invasive-Carpal-Tunnel-Release-Using-PAVmed-s-CarpX-Device.html,same,02/16/2021 09:30,0.226,0.0,0.07200000000000001,0.5859,0.0,0.987,0.3,0.0987878787878788,0.12869975262832406,-0.2857142857142857,3.64,4.49,0.23351648351648352,0.3104395604395603,14924400,4755353
2/17/21,PCSA,33.2,27.33727811,36.09467456,gnw,Processa Pharmaceuticals Announces $10.2 Million Strategic Financing,"Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (‚ÄúProcessa‚Äù or the ‚ÄúCompany‚Äù), a...",https://www.globenewswire.com/news-release/2021/02/17/2177085/0/en/Processa-Pharmaceuticals-Announces-10-2-Million-Strategic-Financing.html,same,02/17/2021 08:00,0.0,0.187,0.11499999999999999,0.0,0.6486,0.9846,0.0,0.0,0.011458333333333334,-0.2222222222222222,8.45,10.76,0.27337278106508883,0.3609467455621303,358381,101409
2/22/21,PAVM,21.4,37.71712159,39.70223325,gnw,PAVmed Announces Proposed Public Offering of Common Stock,"NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ‚ÄúCompany‚Äù or ‚ÄúPAVmed‚Äù), a highly differentiated, multi-product, commercial-stage medical device company, today...",https://www.globenewswire.com/news-release/2021/02/22/2179943/0/en/PAVmed-Announces-Proposed-Public-Offering-of-Common-Stock.html,same,02/22/2021 16:13,0.0,0.0,0.081,0.0,0.0,0.9801,-0.15,0.0987878787878788,0.031411255411255404,-0.08333333333333333,4.03,5.55,0.3771712158808932,0.39702233250620333,13156090,4755353
3/5/21,EYES,304.9,152.8384279,331.8777293,bw,"Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System","Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, to...",http://www.businesswire.com/news/home/20210305005098/en/Second-Sight-Medical-Products-Inc.-Receives-FDA-Approval-for-the-Argus-2s-Retinal-Prosthesis-System,same,03/05/2021 08:00,0.181,0.128,0.154,0.4767,0.5106,0.9878,0.0,-0.13333333333333333,0.05724242424242425,0.5,2.29,5.79,1.5283842794759825,3.3187772925764194,739730593,6372472
3/10/21,AVEO,89.1,85.88807786,86.98296837,bw,AVEO Oncology Announces U.S. FDA Approval of FOTIVDA¬Æ (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA¬Æ (tivozanib) for the treatment of adults with relapsed or refractory advanced renal c...,http://www.businesswire.com/news/home/20210310005893/en/AVEO-Oncology-Announces-U.S.-FDA-Approval-of-FOTIVDA%C2%AE-tivozanib-for-the-Treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Advanced-Renal-Cell-Carcinoma,same,03/10/2021 15:25,0.195,0.146,0.058,0.6249,0.5859,0.9884,0.25,0.4,0.11301764273462388,0.034482758620689655,8.22,15.28,0.8588807785888075,0.8698296836982966,50864569,1400188
3/19/21,CLVS,47.7,22.8125,39.84375,bw,Clovis Oncology‚Äôs Rubraca¬Æ (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca¬Æ (rucaparib) will take place today in an oral presentation at th...",http://www.businesswire.com/news/home/20210319005072/en/Clovis-Oncology%E2%80%99s-Rubraca%C2%AE-rucaparib-Significantly-Improves-Progression-Free-Survival-versus-Chemotherapy-in-Patients-with-Later-line-Ovarian-Cancer-Associated-with-a-BRCA-Mutation,same,03/19/2021 08:00,-0.06399999999999999,0.0,-0.017,-0.3818,0.0,-0.9837,0.375,0.25,0.2797297297297298,-0.35,6.4,7.86,0.228125,0.39843749999999983,331763706,4622851
